ArticleScientific reports2025
Multiplexed, universal probe-based rare variant detection with USE-PCR.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.Molecular diagnosis & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymerase chain reaction (PCR) is an essential tool in research and diagnostics but is limited by the number of resolvable targets, reliance on target-specific probes, and assay-specific data interpretation. To overcome these challenges, we introduce Universal Signal Encoding PCR (USE-PCR), a novel approach combining universal hydrolysis probes, amplitude modulation, multispectral encoding, and standardized analysis for robust, scalable target detection. Using 32 synthetic templates, USE-PCR demonstrates a mean target identification accuracy of 92.6% ± 10.7% at high template copy and 97.6% ± 4.4% at low template copy, with linear correlation coefficients of 0.99 across four dPCR platforms and a dynamic range spanning four orders of magnitude. Integrating USE-PCR with RNase H-based detection chemistry enables 32 single nucleotide variants to be called simultaneously with up to 86.5% accuracy in cancer cell lines. Together, these results position USE-PCR as a transformative platform for high throughput, multiplexed analyte detection with applications in research and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.